UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval

The Lancet. Psychiatry, 2019-12, Vol.6 (12), p.977-979

Turner, Erick H

2019

Volltextzugriff (PDF)

Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials

PLoS medicine, 2022-01, Vol.19 (1), p.e1003886-e1003886

2022

Volltextzugriff (PDF)

Does Publication Bias Inflate the Apparent Efficacy of Psychological Treatment for Major Depressive Disorder? A Systematic Review and Meta-Analysis of US National Institutes of Health-Funded Trials

PloS one, 2015-09, Vol.10 (9), p.e0137864-e0137864

2015

Volltextzugriff (PDF)

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

The New England journal of medicine, 2008-01, Vol.358 (3), p.252-260

2008

Volltextzugriff (PDF)

Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database

PLoS medicine, 2012-03, Vol.9 (3), p.e1001189

2012

Volltextzugriff (PDF)

Reporting of Positive Results in Randomized Controlled Trials of Mindfulness-Based Mental Health Interventions

PloS one, 2016-04, Vol.11 (4), p.e0153220-e0153220

2016

Volltextzugriff (PDF)

An open science pathway for drug marketing authorization—Registered drug approval

PLoS medicine, 2021-08, Vol.18 (8), p.e1003726-e1003726

2021

Volltextzugriff (PDF)

Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis

BMJ open, 2016-07, Vol.6 (7), p.e010919-e010919

2016

Volltextzugriff (PDF)

Rethinking recommendations for screening for depression in primary care

Canadian Medical Association journal (CMAJ), 2012-03, Vol.184 (4), p.413-418

2012

Volltextzugriff (PDF)

Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study

BMJ open, 2020-05, Vol.10 (5), p.e035633-e035633

2020

Volltextzugriff (PDF)

Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009

Systematic reviews, 2020-04, Vol.9 (1), p.77-77, Article 77

2020

Volltextzugriff (PDF)

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

The Lancet (British edition), 2018-04, Vol.391 (10128), p.1357-1366

2018

Volltextzugriff (PDF)

Unpublished trials of alprazolam XR and their influence on its apparent efficacy for panic disorder

Psychological medicine, 2024-04, Vol.54 (5), p.1026-1033

2024

Volltextzugriff (PDF)

Publication Bias, with a Focus on Psychiatry: Causes and Solutions

CNS drugs, 2013-06, Vol.27 (6), p.457-468

Turner, Erick H.

2013

Volltextzugriff (PDF)

Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder

Cochrane database of systematic reviews, 2021-09, Vol.9 (11), p.CD011612

2021

Volltextzugriff (PDF)

WHAT IS THE THRESHOLD FOR A CLINICALLY RELEVANT EFFECT? THE CASE OF MAJOR DEPRESSIVE DISORDERS

Depression and anxiety, 2014-05, Vol.31 (5), p.374-378

2014

Volltextzugriff (PDF)

A taxpayer-funded clinical trials registry and results database

PLoS medicine, 2004-12, Vol.1 (3), p.e60-e60

Turner, Erick H

2004

Volltextzugriff (PDF)

Approval of esketamine for treatment-resistant depression – Author's reply

The Lancet. Psychiatry, 2020-03, Vol.7 (3), p.236-236

Turner, Erick H

2020

Volltextzugriff (PDF)

From the FDA, we still hear mostly thunderous silence

BMJ (Online), 2015-07, Vol.351, p.h3763

Turner, Erick H

2015

Volltextzugriff (PDF)

ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis

BMJ (Online), 2023-11, p.e076754

2023

Volltextzugriff (PDF)

Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials

Psychological medicine, 2019-09, Vol.49 (12), p.2020-2026

2019

Volltextzugriff (PDF)

Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses

JAMA psychiatry (Chicago, Ill.), 2015-05, Vol.72 (5), p.500

2015

Volltextzugriff (PDF)

Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments

JAMA : the journal of the American Medical Association, 2011-03, Vol.305 (10), p.1008

2011

Volltextzugriff (PDF)

Influence of baseline severity on antidepressant efficacy for anxiety disorders: Meta-analysis and meta-regression

British journal of psychiatry, 2016-06, Vol.208 (6), p.515-521

2016

Volltextzugriff (PDF)

Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis

European neuropsychopharmacology, 2016-11, Vol.26 (11), p.1752-1759

2016

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(68)

Publikationsform

Artikel
(92)
Bücher
(1)
Berichte
(1)

Sprache

Englisch
(94)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(66)
Humans
(65)
Life Sciences & Biomedicine
(62)
Psychiatry
(39)
Biological And Medical Sciences
(27)
Female
(27)
Medical Sciences
(26)
Adult
(25)
Male
(25)
Psychology. Psychoanalysis. Psychiatry
(25)
Clinical Trials
(22)
General & Internal Medicine
(20)
Medicine, General & Internal
(20)
Psychopathology. Psychiatry
(20)
Depression
(19)
Middle Aged
(19)
Antidepressive Agents - Therapeutic Use
(16)
Adult And Adolescent Clinical Studies
(15)
Mood Disorders
(15)
Antidepressants
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval

Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials

Does Publication Bias Inflate the Apparent Efficacy of Psychological Treatment for Major Depressive Disorder? A Systematic Review and Meta-Analysis of US National Institutes of Health-Funded Trials

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database

Reporting of Positive Results in Randomized Controlled Trials of Mindfulness-Based Mental Health Interventions

An open science pathway for drug marketing authorization—Registered drug approval

Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis

Rethinking recommendations for screening for depression in primary care

Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study

Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

Unpublished trials of alprazolam XR and their influence on its apparent efficacy for panic disorder

Publication Bias, with a Focus on Psychiatry: Causes and Solutions

Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder

WHAT IS THE THRESHOLD FOR A CLINICALLY RELEVANT EFFECT? THE CASE OF MAJOR DEPRESSIVE DISORDERS

A taxpayer-funded clinical trials registry and results database

Approval of esketamine for treatment-resistant depression – Author's reply

From the FDA, we still hear mostly thunderous silence

ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis

Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials

Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses

Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments

Influence of baseline severity on antidepressant efficacy for anxiety disorders: Meta-analysis and meta-regression

Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis

Suchergebnisse filtern